Ron and his group identify new and support established Worldwide Research & Development (WRD) alliances with numerous universities and biotechnology companies across the globe. Ron also supports Pfizer’s investments into early-stage technologies by leading the Pfizer Seed Fund, enabling scientific opportunities in alignment with Pfizer’s research interests and in partnership with Pfizer Ventures. This fund is intended to help spin out new companies from universities as they are formed, engaging Pfizer scientists as collaborators and advisors while investing alongside other funds in this innovative arena.

After receiving his PhD in Organic Chemistry from the University of Rochester and a postdoctoral fellowship with Nobel Laureate E.J. Corey at Harvard University, he joined Merck Research Laboratories where he founded and led their Strategic Research Initiatives licensing team from 1996-2004. Ron also holds an MBA from Columbia Business School. Following 14 years with Merck, Ron led business development for Sentigen Biosciences (founded by 2004 Nobel Laureate Richard Axel of Columbia University); Celldex Therapeutics; and Auspex Pharmaceuticals, where he served as Chief Business Officer, prior to joining Pfizer in 2010.

Ron has been involved on both sides of M&A transactions, helping to integrate smaller companies into the pharmaceutical culture and ensuring the new employees are welcomed into the larger organization. He has extensive alliance management experience, and manages a team of scientists in over 10 countries who evaluate and propose partnerships of scientific value. He was a Board Observer to Lumena Pharmaceuticals (recently acquired by Shire), is currently Board Observer to Iceni Therapeutics and Neoantigenics, and a Scientific Advisory Board member to Neomed. Ron is a Board Member for the Licensing and Ventures Group at the University of Virginia.